Optimizing Plasmid DNA Manufacturing Strategy: Striking a Balance Between Internal Versus External Production Capacity

Time: 1:00 pm
day: Pre-Conference Workshop Day


In today’s landscape, selecting the right manufacturing strategy for plasmid DNA production is critical. This workshop delves into whether to build internal manufacturing capacity, or outsource to a contract development and manufacturing organization (CDMO). We’ll explore the factors influencing this choice, including CDMO selection criteria, the cost-prohibitive nature of externalizing, the significant time and financial investments associated with building internal capabilities, and how one can effectively develop an internal process.

We will answer pressing questions such as:

  • What are the pros and cons of internalizing versus externalizing plasmid production to make an informed decision about your manufacturing needs?
  • What are the greatest challenges when developing an in-house production platform from scratch to support therapeutic pipelines?
  • What are the key features that drug developers seek in a CDMO when considering whether to outsource plasmid production?